Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | Torin1 | 1 | 72 | 0.1 | 1943.5 | 4174.3 | 1295.5 | -1.0 | 0.272 | 0.466 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 0.32 | 1641.3 | 4174.3 | 1295.5 | -0.495 | 0.150 | 0.393 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 1.0 | 1482.8 | 4174.3 | 1295.5 | 0.0 | 0.083 | 0.355 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 3.2 | 1271.0 | 4174.3 | 1295.5 | 0.505 | -0.011 | 0.304 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.001 | 3973.8 | 4443.3 | 1295.5 | -3.0 | 0.878 | 0.894 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.0032 | 3568.0 | 4443.3 | 1295.5 | -2.49 | 0.768 | 0.803 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.01 | 2662.8 | 4443.3 | 1295.5 | -2.0 | 0.500 | 0.599 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.032 | 2092.5 | 4443.3 | 1295.5 | -1.49 | 0.309 | 0.471 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.1 | 1570.5 | 4443.3 | 1295.5 | -1.0 | 0.114 | 0.353 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.32 | 1150.3 | 4443.3 | 1295.5 | -0.495 | -0.065 | 0.259 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 1.0 | 909.3 | 4443.3 | 1295.5 | 0.0 | -0.181 | 0.205 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 3.2 | 656.5 | 4443.3 | 1295.5 | 0.505 | -0.318 | 0.148 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.001 | 3986.0 | 4308.0 | 1295.5 | -3.0 | 0.912 | 0.925 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.0032 | 3679.3 | 4308.0 | 1295.5 | -2.49 | 0.826 | 0.854 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.01 | 3598.5 | 4308.0 | 1295.5 | -2.0 | 0.803 | 0.835 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.032 | 3544.8 | 4308.0 | 1295.5 | -1.49 | 0.787 | 0.823 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.1 | 3095.0 | 4308.0 | 1295.5 | -1.0 | 0.653 | 0.718 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 0.32 | 2081.3 | 4308.0 | 1295.5 | -0.495 | 0.315 | 0.483 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 1.0 | 1818.5 | 4308.0 | 1295.5 | 0.0 | 0.216 | 0.422 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | Trametinib | 1 | 72 | 3.2 | 1768.0 | 4308.0 | 1295.5 | 0.505 | 0.196 | 0.410 | 1.733 | HCC38 Trametinib 0 1 72 |
| HCC38 | WYE-125132 | 1 | 72 | 0.001 | 4373.3 | 4231.5 | 1295.5 | -3.0 | 1.040 | 1.030 | 1.708 | HCC38 WYE125132 0 1 72 |
| HCC38 | WYE-125132 | 1 | 72 | 0.0032 | 4137.8 | 4231.5 | 1295.5 | -2.49 | 0.974 | 0.978 | 1.708 | HCC38 WYE125132 0 1 72 |
| HCC38 | WYE-125132 | 1 | 72 | 0.01 | 3984.3 | 4231.5 | 1295.5 | -2.0 | 0.931 | 0.942 | 1.708 | HCC38 WYE125132 0 1 72 |
| HCC38 | WYE-125132 | 1 | 72 | 0.032 | 3081.0 | 4231.5 | 1295.5 | -1.49 | 0.661 | 0.728 | 1.708 | HCC38 WYE125132 0 1 72 |
| HCC38 | WYE-125132 | 1 | 72 | 0.1 | 2265.8 | 4231.5 | 1295.5 | -1.0 | 0.387 | 0.535 | 1.708 | HCC38 WYE125132 0 1 72 |